The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAssura Regulatory News (AGR)

Share Price Information for Assura (AGR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.72
Bid: 42.66
Ask: 42.78
Change: 0.12 (0.28%)
Spread: 0.12 (0.281%)
Open: 42.26
High: 42.94
Low: 42.26
Prev. Close: 42.60
AGR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

9 Oct 2023 07:00

RNS Number : 0378P
Assura PLC
09 October 2023

9 October 2023

Assura plc

Trading Update

For the first half ending 30 September 2023

Assura plc ("Assura"), the leading primary care property investor and developer, today announces its Trading Update for the first half of the year to 30 September 2023.

Jonathan Murphy, CEO, said:

"Assura has delivered another period of strong financial performance and disciplined activity.

"We have continued our focus on areas of strategic expansion to unlock value through several attractive portfolio additions. This includes the completion of our state-of-the-art day case hospital in Kettering for Ramsay Healthcare, moving on site with an ambulance hub for the local NHS Trust in Bury St Edmunds which is designed to be net zero carbon in operation, and the acquisition of another high-quality asset in Ireland with a significant asset enhancement opportunity.

"In addition, we made good operational progress in the period. We settled 152 rent reviews to generate an uplift of £1.5 million, and - as separately announced today - we have refinanced our revolving credit facility, increasing the facility size, reducing the costs as a reflection of the strength of the business and adding sustainability-linked KPIs.

"We continue to see growing and consistent demand for high-quality healthcare buildings in a community setting. Our leading market position, strong and sustainable balance sheet and pipeline of growth opportunities will allow us to continue to deliver against our proven strategy."

Strong progress in our areas of strategic focus

· Portfolio of 612 properties with an annualised rent roll of £146.9 million

· Two developments completed in the period (Kettering and Wolverhampton) and one acquisition in Ireland that includes opportunity for a significant asset enhancement project

· Moved on site with an ambulance hub in Bury St Edmunds, which is designed to be net zero carbon in operation

· Completed five asset enhancement capital projects (total spend £3.3 million)

· 152 rent reviews settled in the quarter, covering £19.0 million of existing rent and generating an uplift of £1.5 million

· Quarterly dividend increased by 5% to 0.82 pence per share, as announced at the full year results, with effect from the July 2023 payment

Development and asset enhancement pipelines provide future growth opportunities

· Currently on site with ten developments; these have a remaining spend over the next 12 months of £55 million of a total cost of £114 million (March 2023: 11 on site, £129 million total cost)

· Immediate development pipeline of four schemes, where we would normally expect to be on site within 12 months; total cost of £25 million (March 2023: 5, £37 million). We continue to experience delays on pipeline schemes as we negotiate to ensure rents appropriately reflect the current cost of construction.

· 42 lease re-gears covering £8.2 million of existing rent roll in the current pipeline

· On site with seven asset enhancement capital projects (total spend of £6.9 million over the next 12 months); pipeline of 15 asset enhancement capital projects (projected spend £10 million) over the next two years

Strong and sustainable financial position

· Weighted average interest rate unchanged at 2.30% (March 2023: 2.30%); all drawn debt on fixed rate basis

· Weighted average debt maturity of 6.5 years, no refinancing on drawn debt due until October 2025. Over 50% of drawn debt matures beyond 2030, with our longest maturity debt at our lowest rates

· As separately announced today, revolving credit facility has been refinanced, increasing to £200 million, reducing the overall cost and adding sustainability-linked KPIs

· Net debt of £1,195 million on a fully unsecured basis with cash and undrawn facilities of £259 million (including the refinanced RCF)

Assura's interim results for the first half of the year will be announced on Thursday 16th November 2023.

- ENDS -

Assura plc Jayne Cottam, CFO David Purcell, Investor Relations Director

Tel: 0161 515 2043 Email: Investor@assura.co.uk

FGS Global

Gordon SimpsonGrace Whelan

Anna Tabor

Tel: 0207 251 3801 Email: Assura@fgsglobal.com

Notes to Editors

Assura plc is a national healthcare premises specialist and UK REIT based in Altrincham, UK - caring for more than 600 primary healthcare buildings, from which over six million patients are served.

A constituent of the FTSE 250 and the EPRA* indices, as at 31 March 2023, Assura's portfolio was valued at £2.7 billion.

At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026.

Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.

Further information is available at www.assuraplc.com

Assura plc LEI code: 21380026T19N2Y52XF72

*EPRA is a registered trademark of the European Public Real Estate Association.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTFLFLRISLRIIV
Date   Source Headline
29th Jun 20237:00 amRNSCompletion of 100th development
27th Jun 20234:18 pmRNSHolding(s) in Company
27th Jun 20238:33 amRNSHolding(s) in Company
15th Jun 20237:31 amRNSScrip Calculation Price
14th Jun 20239:01 amRNSHolding(s) in Company
12th Jun 20234:23 pmRNSDirector/PDMR Shareholding
5th Jun 202310:54 amRNSDirector/PDMR Shareholding
2nd Jun 20237:00 amRNSAnnual Report & Notice of AGM
1st Jun 20237:00 amRNSNotice of Dividend
23rd May 20237:00 amRNSAssura Full Year Results 2023
12th May 20237:00 amRNSNotice of Results
10th May 202310:53 amRNSDirector/PDMR Shareholding
28th Apr 20237:00 amRNSTotal Voting Rights
25th Apr 20234:12 pmRNSHolding(s) in Company
17th Apr 20234:06 pmRNSDirector/PDMR Shareholding
11th Apr 20238:43 amRNSDirector/PDMR Shareholding
11th Apr 20237:00 amRNSScrip Dividend Declaration
16th Mar 202310:13 amRNSScrip Calculation Price
13th Mar 20237:00 amRNSMSCI ESG rating upgrade and energy reduction pilot
7th Mar 202310:43 amRNSDirector/PDMR Shareholding
2nd Mar 20237:00 amRNSNotice of Dividend
15th Feb 20231:51 pmRNSHolding(s) in Company
7th Feb 20239:57 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSTotal Voting Rights
26th Jan 20231:48 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSTrading Update
13th Jan 20232:55 pmRNSDirector/PDMR Shareholding
9th Jan 202311:33 amRNSDirector/PDMR Shareholding
9th Jan 20237:00 amRNSScrip Dividend Declaration
15th Dec 20229:07 amRNSScrip calculation price
6th Dec 20229:03 amRNSDirector/PDMR Shareholding
1st Dec 20227:00 amRNSDividend Declaration
22nd Nov 20227:00 amRNSDelivering continued growth
15th Nov 202212:15 pmRNSHolding(s) in Company
8th Nov 20229:02 amRNSDirector/PDMR Shareholding
1st Nov 20222:02 pmRNSHolding(s) in Company
31st Oct 20228:43 amRNSTotal Voting Rights
17th Oct 202212:10 pmRNSDirector/PDMR Shareholding
11th Oct 20221:49 pmRNSHolding(s) in Company
10th Oct 20227:00 amRNSScrip Dividend Declaration
7th Oct 202210:14 amRNSDirector/PDMR Shareholding
5th Oct 20227:00 amRNSTrading Update
15th Sep 20227:00 amRNSScrip calculation price
14th Sep 20225:37 pmRNSDirector/PDMR Shareholding
13th Sep 20224:28 pmRNSHolding(s) in Company
1st Sep 20227:00 amRNSDividend Declaration
8th Aug 202212:51 pmRNSDirector/PDMR Shareholding
29th Jul 20229:27 amRNSTotal Voting Rights
18th Jul 20222:53 pmRNSDirector/PDMR Shareholding
13th Jul 20225:17 pmRNSExercise of Nil Cost Options under PSP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.